PSMD1
Gene Information
- Official Symbol: PSMD1
- Official Name: proteasome 26S subunit, non-ATPase 1
- Aliases and Previous Symbols: N/A
- Entrez ID: 5707
- UniProt: Q99460
- Interactions: BioGRID
- PubMed articles: Open PubMed
- OMIM: Open OMIM
Function Summary
- Entrez Summary: N/A
- UniProt Summary: N/A
Pfam Domains GO Terms
Pfam Domains
| PC rep |
GO Terms
| proteasome storage granule |
| proteasome regulatory particle |
| proteasome regulatory particle, base subcomplex |
| enzyme regulator activity |
| proteasome accessory complex |
| proteasome complex |
| regulation of cellular amino acid metabolic process |
| regulation of hematopoietic stem cell differentiation |
| antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent |
| endopeptidase activity |
| regulation of transcription from RNA polymerase II promoter in response to hypoxia |
| antigen processing and presentation of exogenous peptide antigen via MHC class I |
| NIK/NF-kappaB signaling |
| regulation of cellular amine metabolic process |
| anaphase-promoting complex-dependent catabolic process |
| regulation of hematopoietic progenitor cell differentiation |
| negative regulation of G2/M transition of mitotic cell cycle |
| azurophil granule lumen |
| SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
| interleukin-1-mediated signaling pathway |
| Wnt signaling pathway, planar cell polarity pathway |
| antigen processing and presentation of peptide antigen via MHC class I |
| negative regulation of cell cycle G2/M phase transition |
| regulation of establishment of planar polarity |
| stimulatory C-type lectin receptor signaling pathway |
| innate immune response activating cell surface receptor signaling pathway |
| regulation of stem cell differentiation |
| tumor necrosis factor-mediated signaling pathway |
| regulation of transcription from RNA polymerase II promoter in response to stress |
| regulation of DNA-templated transcription in response to stress |
| non-canonical Wnt signaling pathway |
| positive regulation of canonical Wnt signaling pathway |
| regulation of cellular ketone metabolic process |
| Fc-epsilon receptor signaling pathway |
| cellular response to interleukin-1 |
| negative regulation of canonical Wnt signaling pathway |
| T cell receptor signaling pathway |
| antigen processing and presentation of exogenous peptide antigen |
| positive regulation of Wnt signaling pathway |
| regulation of mRNA stability |
| regulation of morphogenesis of an epithelium |
| antigen processing and presentation of exogenous antigen |
| regulation of RNA stability |
| cellular response to hypoxia |
| antigen processing and presentation of peptide antigen |
| regulation of G2/M transition of mitotic cell cycle |
| cellular response to decreased oxygen levels |
| response to interleukin-1 |
| regulation of mRNA catabolic process |
| negative regulation of Wnt signaling pathway |
| regulation of cell cycle G2/M phase transition |
| negative regulation of mitotic cell cycle phase transition |
| cellular response to oxygen levels |
| antigen processing and presentation |
| negative regulation of cell cycle phase transition |
| innate immune response-activating signal transduction |
| cellular response to tumor necrosis factor |
| Fc receptor signaling pathway |
| regulation of animal organ morphogenesis |
| activation of innate immune response |
| response to tumor necrosis factor |
| protein deubiquitination |
| regulation of canonical Wnt signaling pathway |
| ubiquitin protein ligase binding |
| antigen receptor-mediated signaling pathway |
| protein modification by small protein removal |
| protein polyubiquitination |
| negative regulation of mitotic cell cycle |
| proteasome-mediated ubiquitin-dependent protein catabolic process |
| negative regulation of cell cycle process |
| regulation of mRNA metabolic process |
| positive regulation of innate immune response |
| response to hypoxia |
| proteasomal protein catabolic process |
| Wnt signaling pathway |
| cell-cell signaling by wnt |
| response to decreased oxygen levels |
| regulation of Wnt signaling pathway |
| post-translational protein modification |
| positive regulation of response to biotic stimulus |
| MAPK cascade |
| response to oxygen levels |
| regulation of protein catabolic process |
| signal transduction by protein phosphorylation |
| regulation of mitotic cell cycle phase transition |
| cell surface receptor signaling pathway involved in cell-cell signaling |
| regulation of small molecule metabolic process |
| regulation of cell cycle phase transition |
| immune response-activating cell surface receptor signaling pathway |
| regulation of hemopoiesis |
| regulation of innate immune response |
| positive regulation of defense response |
| immune response-regulating cell surface receptor signaling pathway |
| neutrophil degranulation |
| neutrophil activation involved in immune response |
| neutrophil mediated immunity |
| neutrophil activation |
| granulocyte activation |
| positive regulation of multi-organism process |
| leukocyte degranulation |
| myeloid leukocyte mediated immunity |
| myeloid cell activation involved in immune response |
| regulation of response to biotic stimulus |
| posttranscriptional regulation of gene expression |
| ubiquitin-dependent protein catabolic process |
| modification-dependent protein catabolic process |
| modification-dependent macromolecule catabolic process |
| immune response-activating signal transduction |
| negative regulation of cell cycle |
| myeloid leukocyte activation |
| proteolysis involved in cellular protein catabolic process |
| immune response-regulating signaling pathway |
| positive regulation of response to external stimulus |
| cellular protein catabolic process |
| leukocyte activation involved in immune response |
| cell activation involved in immune response |
| activation of immune response |
| regulation of mitotic cell cycle |
| cytokine-mediated signaling pathway |
| protein catabolic process |
| protein ubiquitination |
| regulated exocytosis |
| regulation of cell cycle process |
| regulation of defense response |
| leukocyte mediated immunity |
| protein modification by small protein conjugation |
| regulation of multi-organism process |
| exocytosis |
| regulation of cellular catabolic process |
| positive regulation of immune response |
| cellular macromolecule catabolic process |
| leukocyte activation |
| protein phosphorylation |
| protein modification by small protein conjugation or removal |
| regulation of catabolic process |
| secretion by cell |
| cellular response to cytokine stimulus |
| export from cell |
| macromolecule catabolic process |
| organonitrogen compound catabolic process |
| regulation of anatomical structure morphogenesis |
| cell activation |
| immune effector process |
| regulation of response to external stimulus |
| response to cytokine |
| cell-cell signaling |
| secretion |
| regulation of immune response |
| positive regulation of immune system process |
| response to abiotic stimulus |
| regulation of cell cycle |
| negative regulation of signal transduction |
| proteolysis |
| transmembrane transport |
| phosphorylation |
| negative regulation of cell communication |
| negative regulation of signaling |
| regulation of response to stress |
| negative regulation of response to stimulus |
| positive regulation of signal transduction |
| regulation of immune system process |
| intracellular signal transduction |
| cellular response to stress |
| organic substance catabolic process |
| cellular catabolic process |
| regulation of cell differentiation |
| positive regulation of cell communication |
| positive regulation of signaling |
| immune response |
| extracellular region |
| vesicle-mediated transport |
| membrane |
CRISPR Data
Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Compound Hit
Most Correlated Genes in Chemogenomics
| Gene | Correlation |
|---|---|
| ZFAND5 | 0.591 |
| VASN | 0.588 |
| PSMD11 | 0.573 |
| SMG1 | 0.568 |
| DDTL | 0.567 |
| PSMC1 | 0.565 |
| PSMD3 | 0.563 |
| PSMD13 | 0.561 |
| HAP1 | 0.547 |
| MT1E | 0.539 |
| SMG7 | 0.539 |
| RPS28 | 0.535 |
| NUPL1 | 0.534 |
| SCAF1 | 0.534 |
| PAN3 | 0.534 |
| ATP13A1 | 0.532 |
| PSMB4 | 0.532 |
| PSMA6 | 0.531 |
| RAD21 | 0.53 |
| ZNF106 | 0.529 |
| BCL2L1 | 0.526 |
| PSMB1 | 0.526 |
| TCEB3CL2 | 0.524 |
| LRR1 | 0.524 |
| KCTD17 | 0.522 |
| PSMC6 | 0.52 |
| CDC45 | 0.514 |
| UPF1 | 0.513 |
| SSH2 | 0.512 |
| CDC73 | 0.512 |
| DNM2 | 0.512 |
| IGFN1 | 0.511 |
| TERF2 | 0.511 |
| RRM1 | 0.507 |
| PSMA7 | 0.505 |
| RPS9 | 0.505 |
| SUPT6H | 0.503 |
| CCNA2 | 0.503 |
| NUP54 | 0.502 |
| RPS2 | 0.501 |
| TWISTNB | 0.5 |
| TBC1D3G | 0.5 |
| RPSA | 0.499 |
| POLE | 0.498 |
| SNRPA1 | 0.497 |
| PSMD6 | 0.497 |
| PSMC2 | 0.497 |
| SMG5 | 0.493 |
| PSMA1 | 0.493 |
| RPS12 | 0.492 |
| PSMD2 | 0.491 |
| TCEB3CL | 0.49 |
| CCDC94 | 0.49 |
| WDR87 | 0.489 |
| PAF1 | 0.489 |
| RRP15 | 0.489 |
| TCEB3C | 0.487 |
| COPE | 0.486 |
| PSMC4 | 0.484 |
| AKIRIN2 | 0.483 |
| MYO1H | 0.483 |
| SFPQ | 0.482 |
| NARFL | 0.477 |
| TBC1D3C | 0.477 |
| TBC1D3F | 0.475 |
| MED17 | 0.472 |
| TBC1D3H | 0.471 |
| DTL | 0.47 |
| CKAP5 | 0.47 |
| HIST1H2BE | 0.47 |
| KPNB1 | 0.469 |
| CWC22 | 0.469 |
| TOP1MT | 0.469 |
| C1QTNF9B | 0.469 |
| C14orf93 | 0.468 |
| POLR2J3 | 0.467 |
| RPL35 | 0.467 |
| DNTTIP2 | 0.467 |
| CDCA3 | 0.467 |
| ANKLE2 | 0.467 |
| MDM2 | 0.467 |
| PSMD14 | 0.466 |
| FBXO5 | 0.466 |
| PWP2 | 0.464 |
| AHCTF1 | 0.464 |
| PSMC3 | 0.464 |
| RRN3 | 0.462 |
| ORC1 | 0.461 |
| S1PR4 | 0.46 |
| RPL26 | 0.46 |
| DDT | 0.458 |
| ARCN1 | 0.457 |
| CHD4 | 0.457 |
| TBC1D3I | 0.455 |
| TBC1D3E | 0.454 |
| PSMD7 | 0.454 |
| TBC1D3K | 0.454 |
| TBC1D3L | 0.453 |
| RBBP5 | 0.452 |
| ADRM1 | 0.45 |
| CHMP2A | 0.448 |
| RILPL1 | 0.448 |
| PSMB2 | 0.447 |
| NOP16 | 0.447 |
| ATXN1 | 0.447 |
| SF3A1 | 0.446 |
| RPS19 | 0.446 |
| CMYA5 | 0.445 |
| HIVEP3 | 0.445 |
| DYNC1I2 | 0.445 |
| POLA2 | 0.444 |
| TICRR | 0.443 |
| ISCU | 0.443 |
| NBPF10 | 0.443 |
| NOL12 | 0.442 |
| WDR43 | 0.442 |
| MYB | 0.442 |
| NBPF16 | 0.44 |
| NOL8 | 0.44 |
| INTS5 | 0.439 |
| LAD1 | 0.439 |
| UTP20 | 0.437 |
| OGFR | 0.437 |
| COX8A | 0.436 |
| NDC1 | 0.436 |
| RANBP2 | 0.435 |
| RBM39 | 0.435 |
| DISP2 | 0.434 |
| GOLGA8J | 0.434 |
| PAN2 | 0.434 |
| CDT1 | 0.433 |
| TBC1D3 | 0.433 |
| NPIPB8 | 0.433 |
| PRPF8 | 0.432 |
| RPS20 | 0.432 |
| CBWD5 | 0.431 |
| HIST2H3A | 0.431 |
| HIST2H3C | 0.431 |
| USP36 | 0.431 |
| TRA2B | 0.43 |
| CTR9 | 0.429 |
| A2ML1 | 0.429 |
| FAM160A1 | 0.429 |
| NUP133 | 0.428 |
| CCDC64B | 0.428 |
| SEC13 | 0.428 |
| NUP160 | 0.427 |
| BYSL | 0.427 |
| RPS19BP1 | 0.423 |
| SLC38A7 | 0.423 |
| POP1 | 0.423 |
| SNIP1 | 0.423 |
| TRAIP | 0.423 |
| DDX21 | 0.423 |
| FBXW9 | 0.422 |
| PSMC5 | 0.422 |
| ZNF830 | 0.422 |
| AAAS | 0.421 |
| EXOSC5 | 0.42 |
| RNF113A | 0.42 |
| RAD51 | 0.419 |
| COPG1 | 0.419 |
| NUP43 | 0.419 |
| CIAPIN1 | 0.419 |
| GOLGA6L6 | 0.419 |
| BTK | 0.419 |
| MADCAM1 | 0.418 |
| CCDC116 | 0.417 |
| RPS5 | 0.417 |
| CDC6 | 0.417 |
| AKAP1 | 0.417 |
| SLC4A1 | 0.416 |
| CSNK1A1 | 0.415 |
| CBWD3 | 0.415 |
| RPL30 | 0.414 |
| RPL8 | 0.414 |
| SEL1L | 0.414 |
| XYLT2 | 0.414 |
| RPL34 | 0.413 |
| DDX56 | 0.413 |
| KRT36 | 0.413 |
| TSPY8 | 0.413 |
| CLPTM1 | 0.412 |
| NAALADL1 | 0.412 |
| CGB2 | 0.411 |
| ORC6 | 0.411 |
| NIP7 | 0.411 |
| PSMB3 | 0.41 |
| PDCD11 | 0.409 |
| SYT9 | 0.407 |
| PPFIA4 | 0.406 |
| SRSF1 | 0.405 |
| WDR75 | 0.405 |
| RPL38 | 0.405 |
| RPS14 | 0.404 |
| SF3A3 | 0.404 |
| ZNF655 | 0.404 |
| RFXANK | 0.404 |
| GNB3 | 0.404 |
| INTS6 | 0.403 |
| COL2A1 | 0.402 |
| NPIPB5 | 0.401 |
| MYT1L | 0.401 |
| EXOSC9 | 0.4 |
| COPB1 | 0.4 |
Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Global Fraction of Cell Lines Where Essential: 614/739
| Tissue | Fraction Of Cell Lines Where Essential |
|---|---|
| 1290807.0 | 1/1 |
| 909776.0 | 1/1 |
| bile duct | 24/28 |
| blood | 26/28 |
| bone | 20/26 |
| breast | 29/33 |
| central nervous system | 47/56 |
| cervix | 4/4 |
| colorectal | 15/17 |
| esophagus | 12/13 |
| fibroblast | 1/1 |
| gastric | 13/16 |
| kidney | 16/21 |
| liver | 18/20 |
| lung | 57/75 |
| lymphocyte | 13/16 |
| ovary | 24/26 |
| pancreas | 19/24 |
| peripheral nervous system | 14/16 |
| plasma cell | 14/15 |
| prostate | 1/1 |
| skin | 23/24 |
| soft tissue | 5/9 |
| thyroid | 2/2 |
| upper aerodigestive | 18/22 |
| urinary tract | 21/29 |
| uterus | 4/5 |
Essentiality in NALM6
- Essentiality Rank: 249
- Expression level (log2 read counts): 7.37
Expression Distribution
PSMD1 Expression in NALM6 Cells: 7.37
